SCHEDULE: Vanguard Group Amends Niagen Bioscience Stake

The Vanguard Group updated its beneficial ownership in Niagen Bioscience Inc., reporting a 4.11% stake as of December 31, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 3,286,498 shares of Niagen Bioscience Inc. Common Stock.
• This represents 4.11% of the class of securities.
• The Vanguard Group holds shared voting power over 446,427 shares and shared dispositive power over 3,286,498 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• The Vanguard Group, Inc. underwent an internal realignment on January 12, 2026, and will no longer perform portfolio management services or administer proxy voting.
• Following the realignment, certain subsidiaries or business divisions of Vanguard are expected to report beneficial ownership separately (on a disaggregated basis).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While a routine disclosure, the continued presence of a significant stake by a major institutional investor like Vanguard provides a baseline level of confidence and liquidity for Niagen Bioscience Inc.

Positives

• The presence of a major institutional investor like The Vanguard Group holding a significant stake (4.11%) can signal market confidence and contribute to stock liquidity.
• The investment is stated to be for ordinary course of business, indicating a passive, stable holding rather than an activist position.

Risks

• The internal realignment of The Vanguard Group, Inc. on January 12, 2026, means that future beneficial ownership reports for Niagen Bioscience Inc. may be disaggregated, potentially leading to a perception of reduced aggregate Vanguard ownership if not properly understood.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine Schedule 13G filings from major asset managers like The Vanguard Group are common disclosures of passive investment stakes. The continued presence of such institutional ownership in Niagen Bioscience Inc. suggests a degree of market liquidity and institutional interest, aligning with typical investment strategies for broad market index funds or passively managed portfolios.

Stakeholder Impact

• Shareholders benefit from transparency regarding significant institutional ownership, which can indicate market confidence and liquidity.
• The internal realignment at Vanguard primarily impacts Vanguard's internal operations and reporting structure, with a secondary effect on how its beneficial ownership in Niagen Bioscience Inc. will be disclosed in the future.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of a passive investment by a major institutional investor. It does not contain information about the issuer's financial performance, strategic direction, or any events that would fundamentally alter its valuation. The presence of Vanguard as a significant shareholder is generally a neutral to slightly positive indicator of market liquidity and institutional interest, supporting a 'hold' recommendation for existing investors based solely on this filing.

Keywords

Niagen Bioscience Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake